To evaluate the effectiveness of an ultra-low dose of the PD1 inhibitor nivolumab combined with chemotherapy for patients with advanced head and neck squamous cell carcinoma in resource-limited countries.
Key Findings:
Patients receiving TMC-I had a median overall survival of 10.3 months compared to 6.2 months for standard chemotherapy.
46% of TMC-I patients were alive after one year, versus 23% in the control group.
TMC-I was associated with fewer severe side effects, with grade 3 or higher adverse events about 10 percentage points lower than in the standard chemotherapy group.
Interpretation:
TMC-I has become the preferred first-line regimen in India based on its efficacy and lower cost compared to standard therapies.
Limitations:
Overall survival outcomes with TMC-I remain lower than those reported with first-line agents in the U.S.
Further studies are needed to compare standard-dose and low-dose immunotherapy approaches.
Conclusion:
The findings suggest that reduced dosage strategies could improve access to cancer therapies in low-income nations and may inform dosing strategies in higher-resource settings.
